| Over a month ago |
|
Recommendations
|
Barclays analyst Peter… Barclays analyst Peter Lawson views the Financial Times' report that GSK (GSK) has interest in acquiring companies with a market capitalization in the $1.0B-$2.5B range, are under-the-radar, and with drugs that can be approved in the medium term as positive for the biotech tape. Renewed acquisition activity would help improve biotech sentiment and the overall index performance, Lawson tells investors in a research note. He sees a positive read-through to oncology companies with late-stage assets, namely Arvinas (ARVN), Replimune Group (REPL), Kura Oncology (KURA), Iovance Biotherapeutics (IOVA), Syndax (SNDX), SpringsWorks Therapeutics (SWTX), Bicycle Therapeutics (BCYC) and Karyopharm (KPTI). ShowHide Related Items >><< SWTX SpringsWorks Therapeutics - 12/27/22
- SpringsWorks Therapeutics completes submission of nirogacestat NDA to FDA
- 11/01/22
- Applied BioMath announces collaboration with SpringsWorks
- 09/29/22
- SpringsWorks Therapeutics doses first patient in Phase 2 trial of nirogacestat
- 09/10/22
- SpringWorks Therapeutics announces data from Phase 3 DeFi trial
- 12/05/22
- Syndax: FDA grants Breakthrough Therapy Designation for revumenib
- 12/05/22
- Syndax, Incyte report axatilimab Phase 1/2 data
- 12/02/22
- Syndax names Steve Sabus as Chief Commercial Officer
- 11/03/22
- Syndax lowers FY22 research and development expenses view to $115M-$125M
- 12/07/22
- Replimune Group announces updates on RP2/3 data, development plans
- 12/07/22
- Replimune Group announces initial data from IGNYTE trial on RP1
- 12/07/22
- Replimune Group enters collaboration agreement with Roche
- 11/03/22
- Replimune Group: Financing extends cash runway into 2025
- 12/12/22
- Kura Oncology trading resumes
- 12/12/22
- Kura Oncology trading halted, volatility trading pause
- 12/11/22
- Kura Oncology presents updated clinical data from KOMET-001 trial
- 11/03/22
- Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital
- 12/12/22
- Karyopharm announces updated results from Phase 1 selinexor data
- 11/03/22
- Karyopharm to present new selinexor data in myelofibrosis and myeloma
- 11/01/22
- Karyopharm, Menarini Group: EC grants orphan designation for selinexor
- 10/31/22
- Karyopharm and Menarini announce EC granted orphan designation for selinexor
IOVA Iovance Biotherapeutics - 12/02/22
- Iovance rallies after director buys $65M worth of shares
- 11/18/22
- Iovance Biotherapeutics: BLA for lifileucel expected to be completed in 1Q23
- 11/10/22
- Iovance Biotherapeutics announces updated clinical data for lifileucel
- 11/07/22
- Iovance Biotherapeutics announces updated clinical data for Lifileucel
- 12/26/22
- Fly Intel: Top five weekend stock stories
- 12/13/22
- Wave Life Sciences, GSK collaborate for oligonucleotide therapeutic development
- 12/12/22
- GSK announces new global headquarters in central London
- 12/11/22
- GSK announces new 48-week data from MOMENTUM Phase 3 trial
BCYC Bicycle Therapeutics - 11/08/22
- Bicycle says BT8009 exhibits potential best-in-class ant-tumor activivity
- 10/10/22
- Bicycle Therapeutics publishes article with preclinical data from BT8009 program
- 09/19/22
- Molecular Cancer Therapeutics publishes data on Bicycle Therapeutics' BT8009
- 09/07/22
- Bicycle Therapeutics announces BT5528 Phase I dose escalation results
- 12/16/22
- Arvinas appoints Everett Cunningham to board of directors
- 11/22/22
- Arvinas says ARV-471 achieves clinical benefit rate of 38% in evaluable patients
- 11/08/22
- Arvinas expects cash to fund operations multiple years beyond 2024
- 10/03/22
- Arvinas appoints Paul McInulty as SVP, regulatory affairs
- 01/02/23 Wells Fargo
- Arvinas downgraded to Equal Weight from Overweight at Wells Fargo
- 12/05/22 Citi
- Arvinas price target lowered to $72 from $88 at Citi
- 11/23/22 Truist
- Arvinas price target lowered to $100 from $170 at Truist
- 11/23/22 Cantor Fitzgerald
- Arvinas price target lowered to $90 from $106 at Cantor Fitzgerald
- 12/23/22 Raymond James
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- 12/21/22 Barclays
- Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
- 12/15/22 Guggenheim
- Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
- 12/08/22 AlphaValue/Baader
- GSK upgraded to Buy from Add at AlphaValue/Baader
- 12/20/22 Piper Sandler
- Piper recommends 'down market cap' biotech exposure for 2023
- 12/14/22 Piper Sandler
- Replimune Group price target raised to $58 from $43 at Piper Sandler
- 12/12/22 BMO Capital
- Replimune Group price target raised to $70 from $40 at BMO Capital
- 10/14/22 BMO Capital
- Replimune Group price target raised to $40 from $30 at BMO Capital
- 07/12/22 Cantor Fitzgerald
- Kura Oncology initiated with an Overweight at Cantor Fitzgerald
- 07/12/22 Cantor Fitzgerald
- Kura Oncology initiated with an Overweight at Cantor Fitzgerald
- 02/15/22 Jefferies
- Kura Oncology initiated with a Buy at Jefferies
IOVA Iovance Biotherapeutics - 12/08/22 Goldman Sachs
- Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs
- 11/21/22 JMP Securities
- Iovance Biotherapeutics price target lowered to $21 from $25 at JMP Securities
- 11/20/22 Piper Sandler
- Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
- 11/18/22 Chardan
- Iovance Biotherapeutics price target lowered to $29 from $30 at Chardan
- 12/12/22 H.C. Wainwright
- Syndax price target raised to $33 from $31 at H.C. Wainwright
- 09/20/22 B. Riley
- B. Riley replaces Allogene with Syndax as top pick for 2022
- 07/28/22 B. Riley
- Syndax resumed with a Buy at B. Riley
- 04/11/22 H.C. Wainwright
- Syndax initiated with a Buy at H.C. Wainwright
SWTX SpringsWorks Therapeutics - 12/01/22 BofA
- SpringsWorks Therapeutics initiated with a Buy, $45 price target at BofA
- 12/01/22 BofA
- SpringsWorks Therapeutics initiated with a Buy at BofA
- 09/12/22 H.C. Wainwright
- SpringsWorks price target raised to $103 from $94 at H.C. Wainwright
- 08/09/22 H.C. Wainwright
- SpringsWorks Therapeutics price target lowered to $94 from $95 at H.C. Wainwright
BCYC Bicycle Therapeutics - 11/10/22 Piper Sandler
- Bicycle Therapeutics price target raised to $48 from $37 at Piper Sandler
- 11/09/22 JMP Securities
- Bicycle Therapeutics price target lowered to $46 from $70 at JMP Securities
- 08/31/22 Cowen
- Cowen starts Bicycle at Outperform with positive data 'any day now'
- 08/31/22 Cowen
- Bicycle Therapeutics initiated with an Outperform at Cowen
- 11/04/22 RBC Capital
- Karyopharm upgraded to Outperform from Sector Perform at RBC Capital
- 11/04/22 RBC Capital
- Karyopharm upgraded to Outperform from Sector Perform at RBC Capital
- 08/05/22 Baird
- Karyopharm price target lowered to $14 from $17 at Baird
- 08/05/22 Barclays
- Karyopharm price target lowered to $8 from $14 at Barclays
SWTX SpringsWorks Therapeutics - 11/03/22
- SpringsWorks Therapeutics reports Q3 EPS ($1.37), consensus ($1.32)
- 08/04/22
- SpringsWorks Therapeutics reports Q2 EPS ($1.41), consensus ($1.20)
- 11/03/22
- Syndax reports Q3 EPS (58c), consensus (63c)
- 08/08/22
- Syndax reaffirms FY22 research and development expenses view $130M-$140M
- 08/08/22
- Syndax sees Q3 research and development expenses $25M-$30M
- 08/08/22
- Syndax reports Q2 EPS (62c), consensus (65c)
- 11/03/22
- Replimune Group reports Q2 EPS (79c), consensus (78c)
- 08/04/22
- Replimune Group reports Q1 EPS (78c) vs (53c) last year
- 11/03/22
- Kura Oncology reports Q3 EPS (53c), consensus (56c)
- 08/03/22
- Kura Oncology reports Q2 EPS (52c), consensus (52c)
- 11/03/22
- Karyopharm sees FY22 revenue $155M-$165M, consensus $157.23M
- 11/03/22
- Karyopharm reports Q3 EPS (45) with items, consensus (57c)
- 08/04/22
- Karyopharm sees 2022 revenue $155M-$165M, consensus $160.03M
- 08/04/22
- Karyopharm reports Q2 EPS (62c), consensus (63c)
IOVA Iovance Biotherapeutics - 11/03/22
- Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c)
- 08/04/22
- Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c)
- 11/02/22
- GSK reports Q3 adjusted EPS 46.9p, up 25% AER, 11% CER
- 07/27/22
- GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
BCYC Bicycle Therapeutics - 11/03/22
- Bicycle Therapeutics reports Q3 EPS (96c), consensus (89c)
- 08/04/22
- Bicycle Therapeutics reports Q2 EPS (90c), consensus (85c)
- 11/08/22
- Arvinas reports Q3 EPS ($1.24), consensus ($1.13)
- 08/04/22
- Arvinas reports Q2 EPS ($1.32), consensus ($1.04)
|
|
On The Fly
| ShowHide Related Items >><< - $100.80 /
+1.245 (+1.25%) - 11/14/22
- Third Point buys TJX, exits Cenovus Energy in Q3
- 11/14/22
- U.S. game content spending grew 2% y/y in October, says NPD
- 11/14/22
- U.S. video game spending totaled $4.3B in October, says NPD
- 11/10/22
- Sony says 'Modern Warfare II' tops PS5 digital downloads in October
- 12/05/22
- Patterson-UTI reports an average of 131 drilling rigs operating in November
- 11/03/22
- Patterson-UTI reports an average of 131 drilling rigs operating in October
- 10/05/22
- Patterson-UTI reports an average of 130 drilling rigs operating in September
- 09/06/22
- Patterson-UTI reports average of 127 U.S. drilling rigs operating in August
- 12/06/22
- Netflix CEO Sarandos sees multiple ad tiers over time
- 12/01/22
- Enthusiast Gaming, Netflix enter content partnership for Geeked: Toon-in
- 11/14/22
- Appaloosa exits positions in Kohl's, Occidental Petroleum, Micron
- 11/07/22
- Netflix to adapt video game 'Gears of War' into feature film, animated series
- 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 10/05/22
- Xponential Fitness debuts workouts on Lululemon Studio
- 09/30/22
- Peloton, Lululemon reach settlement over athletic wear
JAZZ Jazz Pharmaceuticals - 11/29/22
- Zymeworks says Hart-Scott-Rodino wait expires for Zanidatamab deal with Jazz
- 11/28/22
- Jazz to present six presentations on advancements in epilepsy outcomes
- 11/18/22
- Avadel says Delaware Court ordered Jazz to delist REMS Patent from Orange Book
- 11/18/22
- Jazz announces FDA approval of sBLA for Rylaze dosing schedule
IOVA Iovance Biotherapeutics - 12/02/22
- Iovance rallies after director buys $65M worth of shares
- 11/18/22
- Iovance Biotherapeutics: BLA for lifileucel expected to be completed in 1Q23
- 11/10/22
- Iovance Biotherapeutics announces updated clinical data for lifileucel
- 11/07/22
- Iovance Biotherapeutics announces updated clinical data for Lifileucel
- 12/08/22
- DocuSign jumps 14% to $49.80 after Q3 results beat estimates
- 12/08/22
- DocuSign reports Q3 adjusted gross margin 83% vs. 82% last year
- 10/04/22
- Cathie Wood says moved out of DocuSign, did not understand competition
- 09/28/22
- DocuSign announces restructuring plan, to reduce workforce by 9%
- 12/08/22
- Carvana rises 15.7%
- 12/08/22
- Carvana rises 8.0%
- 12/07/22
- Carvana falls -36.1%
- 12/07/22
- Carvana falls -33.1%
- 12/02/22
- Credit Suisse rallies after Chairman says outflows 'basically stopped'
- 11/23/22
- Credit Suisse sees likely loss for Wealth Management in Q4
- 11/23/22
- Credit Suisse sees 'substantial' loss of up to CHF 1.5B in Q4
- 11/23/22
- Credit Suisse confirms capital ratio guidance from October 27
- 12/02/22
- Coinbase says Apple blocked last app release on NFTs
- 11/30/22
- Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP
- 11/21/22
- Crypto names down in pre-market as bitcoin falls to one-week low
- 11/16/22
- Cathie Wood's ARK Investment bought 245.6K shares of Coinbase today
- 12/02/22
- CleanSpark releases November 2022 bitcoin mining update
- 12/01/22
- CleanSpark expands board of directors with appointment of Cavaleri
- 11/03/22
- CleanSpark reports 532 bitcoin mined in October
- 11/01/22
- CleanSpark expand bitcoin mining with purchase of 3,853 latest gen machines
- $531.27 /
+12.72 (+2.45%) - 12/08/22
- Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M
- 12/08/22
- Broadcom raises quarterly dividend 12% to $4.60 per share
- 10/25/22
- Broadcom's Rally Software receives FedRAMP authorization
- 10/18/22
- Broadcom showcases hyperscale solutions at 2022 OCP Global Summit
- 12/06/22
- Alight acquires ReedGroup, financial terms not disclosed
- 11/16/22
- Alight director buys $840.5K in common stock
- 11/14/22
- Alight falls -13.7%
- 11/14/22
- Alight falls -13.2%
- 11/11/22
- London Metal Exchange decides against Russian metal ban
- 10/19/22
- Alcoa falls 8.3% to $34.50 afterhours following Q3 earnings miss
- 10/19/22
- Alcoa backs 2022 total Aluminum segment shipments view of 2.5-2.6M Mt
- 10/19/22
- Alcoa reports Q3 adjusted EBITDA of $210M, down 77% from Q2
- 12/09/22 Cowen
- Netflix price target raised to $405 at Cowen, named a 'Best Idea for 2023'
- 12/09/22 Wells Fargo
- Wells Fargo upgrades Netflix shares on 'more ways to win' in 2023
- 12/09/22 Wells Fargo
- Netflix upgraded to Overweight from Equal Weight at Wells Fargo
- 11/30/22 Societe Generale
- Netflix price target raised to $215 from $170 at Societe Generale
- 12/09/22 BofA
- DocuSign price target lowered to $65 from $80 at BofA
- 12/09/22 Piper Sandler
- DocuSign upgraded to Neutral from Underweight at Piper Sandler
- 12/06/22 Citi
- DocuSign price target lowered to $59 from $76 at Citi
- 12/05/22 UBS
- DocuSign price target lowered to $52 from $65 at UBS
- 12/09/22 Mizuho
- Coinbase downgraded to Underperform from Neutral at Mizuho
- 12/05/22 Atlantic Equities
- Coinbase price target lowered to $46 from $67 at Atlantic Equities
- 12/02/22 Piper Sandler
- Piper calls for 'more aggressive headcount reduction' at Coinbase
- 11/22/22 Needham
- Coinbase price target lowered to $73 from $89 at Needham
- $531.27 /
+12.72 (+2.45%) - 12/09/22 Truist
- Broadcom price target raised to $662 from $630 at Truist
- 12/09/22 BofA
- Broadcom price target raised to $650 from $625 at BofA
- 12/09/22 Wells Fargo
- Broadcom resumed with an Equal Weight at Wells Fargo
- 12/09/22 Cowen
- Broadcom price target raised to $555 from $540 at Cowen
- 12/09/22 Cantor Fitzgerald
- Cantor starts bitcoin miner CleanSpark at Overweight, says overlooked
- 12/09/22 Cantor Fitzgerald
- CleanSpark initiated with an Overweight at Cantor Fitzgerald
- 08/10/22 H.C. Wainwright
- CleanSpark price target raised to $12 from $6 at H.C. Wainwright
- 07/26/22 H.C. Wainwright
- CleanSpark assumed with a Buy at H.C. Wainwright
- 12/09/22 Jefferies
- Vroom price target lowered to $1.10 from $1.30 at Jefferies
- 12/09/22 Jefferies
- Carvana price target lowered to $5 from $10 at Jefferies
- 12/09/22 Needham
- Needham downgrades Carvana, struggles to see near-term path forward
- 12/09/22 Needham
- Carvana downgraded to Hold from Buy at Needham
- $100.80 /
+1.245 (+1.25%) - 12/09/22 Citi
- Take-Two initiated with a Neutral at Citi
- 11/28/22 Morgan Stanley
- Take-Two price target lowered to $145 from $150 at Morgan Stanley
- 11/17/22 Truist
- Take-Two price target lowered to $131 from $157 at Truist
- 11/16/22 Truist
- Take-Two price target lowered to $131 from $157 at Truist
JAZZ Jazz Pharmaceuticals - 12/08/22 Goldman Sachs
- Jazz Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
- 11/30/22 Jefferies
- Avadel upgraded to Buy at Jefferies after survey of sleep doctors
- 11/21/22 Needham
- Avadel Pharmaceuticals price target raised to $9 from $8 at Needham
- 11/01/22 H.C. Wainwright
- H.C. Wainwright downgrades Zymeworks on Jazz opt-out possibility
- 12/09/22 BofA
- BofA upgrades Credit Suisse to Buy, sees more than 20% upside potential
- 12/09/22 BofA
- Credit Suisse upgraded to Buy from Neutral at BofA
- 12/01/22 JPMorgan
- Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan
- 11/07/22 AlphaValue/Baader
- Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
NHI National Health Investors - 12/09/22 Credit Suisse
- National Health upgraded to Neutral from Underperform at Credit Suisse
- 09/26/22 Truist
- National Health Investors price target lowered to $61 from $64 at Truist
- 08/01/22 Credit Suisse
- Credit Suisse sees SNF-exposed REITs reacting positively to reimbursement ruling
- 06/22/22 Credit Suisse
- National Health Investors initiated with an Underperform at Credit Suisse
IOVA Iovance Biotherapeutics - 12/08/22 Goldman Sachs
- Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs
- 11/21/22 JMP Securities
- Iovance Biotherapeutics price target lowered to $21 from $25 at JMP Securities
- 11/20/22 Piper Sandler
- Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
- 11/18/22 Chardan
- Iovance Biotherapeutics price target lowered to $29 from $30 at Chardan
- 12/09/22 Morgan Stanley
- Alcoa downgraded to Equal Weight from Overweight at Morgan Stanley
- 10/21/22 B. Riley
- Alcoa price target lowered to $37 from $51 at B. Riley
- 10/20/22 BMO Capital
- Alcoa price target lowered to $35 from $40 at BMO Capital
- 10/06/22 UBS
- Alcoa initiated with a Neutral at UBS
- 12/09/22 Morgan Stanley
- Lululemon price target raised to $387 from $343 at Morgan Stanley
- 12/09/22 Jefferies
- Jefferies says 'sell shares now' with Lululemon Q3 'as good as it gets'
- 12/09/22 Wells Fargo
- Lululemon price target raised to $360 from $345 at Wells Fargo
- 12/09/22 Goldman Sachs
- Lululemon removed from Conviction Buy list at Goldman on tough comps
- 12/09/22 Wedbush
- Alight initiated with an Outperform at Wedbush
- 12/06/22 Needham
- Alight initiated with a Buy at Needham
- 11/08/22 KeyBanc
- KeyBanc cuts Benefitfocus to Sector Weight after Q3 results, pending acquisition
- 09/15/22 KeyBanc
- Alight initiated with an Overweight at KeyBanc
- 12/09/22 Raymond James
- Patterson-UTI initiated with a Strong Buy at Raymond James
- 10/07/22 Piper Sandler
- Patterson-UTI assumed with an Overweight at Piper Sandler
- 09/13/22 Susquehanna
- US well completions flat in August but outlook positive, says Susquehanna
- 08/01/22 Barclays
- Patterson-UTI price target raised to $24 from $20 at Barclays
- $100.80 /
+1.245 (+1.25%) - 11/08/22
- Take-Two sees FY23 revenue $5.41B-$5.51B, consensus $5.89B
- 11/07/22
- Take-Two sees Q3 revenue $1.43B-$1.48B, consensus $1.43B
- 11/07/22
- Take-Two reports Q2 GAAP EPS ($1.54)
- 11/07/22
- Notable companies reporting after market close
- 10/26/22
- Patterson-UTI reports Q3 EPS 28c, consensus 18c
- 07/27/22
- Patterson-UTI reports Q2 EPS 10c, consensus (4c)
- 10/18/22
- Netflix sees Q4 EPS 36c, consensus $1.12
- 10/18/22
- Netflix reports Q3 EPS $3.10, consensus $2.13
- 10/18/22
- Notable companies reporting after market close
- 07/19/22
- Netflix sees Q3 EPS $2.14, consensus $2.77
- 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
JAZZ Jazz Pharmaceuticals - 11/09/22
- Jazz Pharmaceuticals raises FY22 EPS view to $17.20-$17.85 from $16.70-$17.70
- 11/09/22
- Jazz Pharmaceuticals reports Q3 adjusted EPS $5.17, consensus $4.66
- 08/03/22
- Jazz Pharmaceuticals backs FY22 revenue view $3.5B-$3.7B, consensus $3.6B
- 08/03/22
- Jazz Pharmaceuticals backs FY22 non-GAAP EPS view $16.70-$17.70
IOVA Iovance Biotherapeutics - 11/03/22
- Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c)
- 08/04/22
- Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c)
- 12/08/22
- DocuSign sees FY23 revenue $2.493B-$2.497B, consensus $2.49B
- 12/08/22
- DocuSign sees Q4 revenue $637M-$641M, consensus $640.51M
- 12/08/22
- DocuSign reports Q3 adjusted EPS 57c, consensus 42c
- 12/08/22
- Notable companies reporting after market close
- 11/03/22
- Carvana sees sequential reduction in retail units sold in Q4
- 11/03/22
- Carvana reports Q3 EPS ($2.67), consensus ($1.94)
- 08/04/22
- Carvana reports Q2 EPS ($2.35), consensus ($1.79)
- 10/27/22
- Credit Suisse reports Q3 net revenue CHF 3.8B vs. CHF 5.43B last year
- 07/27/22
- Credit Suisse reports Q2 net revenue CHF3.6B vs. CHF5.1B last year
- 12/07/22
- Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more
- 11/03/22
- Coinbase reports Q3 EPS ($2.43), consensus ($2.40)
- 11/03/22
- Notable companies reporting after market close
- 08/09/22
- Coinbase reports Q2 EPS ($4.98), consensus ($2.65)
- 08/09/22
- CleanSpark reports Q3 cont ops EPS (39c), consensus (10c)
- $531.27 /
+12.72 (+2.45%) - 12/08/22
- Broadcom sees Q1 revenue $8.9B, consensus $8.79B
- 12/08/22
- Broadcom reports Q4 EPS $10.45, consensus $10.28
- 09/01/22
- Broadcom sees Q4 revenue $8.9B, consensus $8.73B
- 11/03/22
- Alight backs 2022 adjusted EPS view 54c-60c, consensus 49c
- 11/03/22
- Alight reports Q3 adjusted EPS 12c, consensus 6c
- 08/03/22
- Alight backs FY22 adjusted EPS view 54c-60c, consensus 58c
- 08/03/22
- Alight reports Q2 EPS 10c, consensus 12c
- 10/19/22
- Alcoa reports Q3 EPS (33c), consensus 19c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Alcoa reports Q2 adjusted EPS $2.67, consensus $2.31
- 07/20/22
- Notable companies reporting after market close
|
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - $266.37 /
+4.545 (+1.74%) - 12/08/22
- RH says Q3 gross margin contracted 50bps
- 12/08/22
- RH to acquire Dmitriy & Co
- 12/08/22
- RH CEO to exercise expiring options
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 09/08/22
- Phreesia rises 15.2%
- 09/08/22
- Phreesia rises 16.8%
- 06/22/22
- Phreesia rises 8.8%
- 12/08/22
- Vail Resorts still sees FY23 net income $321M-$396M
- 11/28/22
- Vail Resorts names Angela Korch CFO
- 09/28/22
- Vail Resorts sees FY23 reported EBITDA $890M-$950M vs. $833M in FY22
- 08/22/22
- Vail Resorts to limit lift tickets throughout 2022/2023 season
- 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 10/05/22
- Xponential Fitness debuts workouts on Lululemon Studio
- 09/30/22
- Peloton, Lululemon reach settlement over athletic wear
JAZZ Jazz Pharmaceuticals - 11/29/22
- Zymeworks says Hart-Scott-Rodino wait expires for Zanidatamab deal with Jazz
- 11/28/22
- Jazz to present six presentations on advancements in epilepsy outcomes
- 11/18/22
- Avadel says Delaware Court ordered Jazz to delist REMS Patent from Orange Book
- 11/18/22
- Jazz announces FDA approval of sBLA for Rylaze dosing schedule
IOVA Iovance Biotherapeutics - 12/02/22
- Iovance rallies after director buys $65M worth of shares
- 11/18/22
- Iovance Biotherapeutics: BLA for lifileucel expected to be completed in 1Q23
- 11/10/22
- Iovance Biotherapeutics announces updated clinical data for lifileucel
- 11/07/22
- Iovance Biotherapeutics announces updated clinical data for Lifileucel
- 12/08/22
- DocuSign jumps 14% to $49.80 after Q3 results beat estimates
- 12/08/22
- DocuSign reports Q3 adjusted gross margin 83% vs. 82% last year
- 10/04/22
- Cathie Wood says moved out of DocuSign, did not understand competition
- 09/28/22
- DocuSign announces restructuring plan, to reduce workforce by 9%
- 09/08/22
- Torrid falls -9.5%
- 09/08/22
- Torrid falls -12.8%
- 08/19/22
- Torrid falls -15.5%
- 08/18/22
- Torrid falls -13.7%
- 12/08/22
- Chewy says now expects FY22 capex to come in slightly below 2.5% of sales
- 10/20/22
- Chewy expands CarePlus with new plan by Lemonade Pet
- 08/31/22
- Chewy falls -7.3%
- 08/30/22
- Chewy sees FY22 adjusted EBITDA margin 1.75%-2%
- 12/08/22
- Bath & Body Works up 9% after Third Point reveals stake, voices concerns
- 12/08/22
- Third Point reports 6.02% stake in Bath & Body Works
- 11/17/22
- Bath & Body Works rises 19.7%
- 11/17/22
- Bath & Body Works rises 24.8%
- $531.27 /
+12.72 (+2.45%) - 12/08/22
- Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M
- 12/08/22
- Broadcom raises quarterly dividend 12% to $4.60 per share
- 10/25/22
- Broadcom's Rally Software receives FedRAMP authorization
- 10/18/22
- Broadcom showcases hyperscale solutions at 2022 OCP Global Summit
- 12/06/22 Citi
- DocuSign price target lowered to $59 from $76 at Citi
- 12/05/22 UBS
- DocuSign price target lowered to $52 from $65 at UBS
- 12/05/22 Baird
- DocuSign price target lowered to $50 from $70 at Baird
- 11/30/22 Jefferies
- DocuSign initiated with a Hold at Jefferies
- $531.27 /
+12.72 (+2.45%) - 12/05/22 Susquehanna
- Broadcom price target lowered to $650 from $680 at Susquehanna
- 12/05/22 Piper Sandler
- Broadcom price target lowered to $715 from $750 at Piper Sandler
- 10/27/22 Jefferies
- Meta commentary positive for datacenter semi names, says Jefferies
- 10/18/22 Deutsche Bank
- Broadcom price target lowered to $575 from $635 at Deutsche Bank
- 10/13/22 DA Davidson
- Phreesia initiated at Neutral at DA Davidson yesterday on valuation
- 10/12/22 DA Davidson
- Phreesia initiated with a Neutral at DA Davidson
- 09/15/22 KeyBanc
- Phreesia initiated with an Overweight at KeyBanc
- 09/08/22 Piper Sandler
- Piper Sandler ups Phreesia price target to $33 following 'strong' Q2 beat
- $266.37 /
+4.545 (+1.74%) - 11/21/22 Barclays
- RH downgraded to Equal Weight from Overweight at Barclays
- 11/18/22 Wedbush
- Wedbush downgrades RH on 'course-correction,' deteriorating macro
- 11/18/22 Wedbush
- RH downgraded to Neutral from Outperform at Wedbush
- 10/31/22 Citi
- RH price target lowered to $305 from $338 at Citi
- 09/29/22 Truist
- Vail Resorts price target lowered to $270 from $281 at Truist
- 09/29/22 Deutsche Bank
- Vail Resorts price target lowered to $283 from $286 at Deutsche Bank
- 09/29/22 Barclays
- Vail Resorts price target raised to $224 from $217 at Barclays
- 09/26/22 Stifel
- Vail Resorts price target lowered to $228 from $273 at Stifel
- 12/07/22 Argus
- Bath & Body Works price target raised to $50 from $45 at Argus
- 11/28/22 Goldman Sachs
- Goldman finds small crowds, more promotions over Black Friday weekend
- 11/18/22 Citi
- Bath & Body Works price target raised to $50 from $48 at Citi
- 11/17/22 Morgan Stanley
- Bath & Body Works price target raised to $76 from $72 at Morgan Stanley
JAZZ Jazz Pharmaceuticals - 12/08/22 Goldman Sachs
- Jazz Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
- 11/30/22 Jefferies
- Avadel upgraded to Buy at Jefferies after survey of sleep doctors
- 11/21/22 Needham
- Avadel Pharmaceuticals price target raised to $9 from $8 at Needham
- 11/01/22 H.C. Wainwright
- H.C. Wainwright downgrades Zymeworks on Jazz opt-out possibility
- 09/22/22 Morgan Stanley
- Torrid price target lowered to $5 from $6.50 at Morgan Stanley
- 08/04/22 Baird
- Torrid price target lowered to $7 from $9 at Baird
- 07/21/22 Goldman Sachs
- Torrid price target lowered to $4 from $5.50 at Goldman Sachs
- 07/15/22 Cowen
- Torrid downgraded to Market Perform at Cowen on low income consumer exposure
- 12/07/22 Deutsche Bank
- Lululemon price target raised to $450 from $434 at Deutsche Bank
- 12/06/22 Raymond James
- Lululemon price target raised to $438 from $345 at Raymond James
- 12/05/22 Stifel
- Lululemon price target raised to $450 from $400 at Stifel
- 12/05/22 Cowen
- Lululemon price target raised to $542 from $535 at Cowen
- 12/07/22 Wolfe Research
- Chewy downgraded to Peer Perform from Outperform at Wolfe Research
- 11/28/22 Wedbush
- Black Friday winners Include Best Buy, losers include Pets, says Wedbush
- 11/21/22 Deutsche Bank
- Chewy price target raised to $50 from $40 at Deutsche Bank
- 11/15/22 MoffettNathanson
- Chewy initiated with a Market Perform at MoffettNathanson
IOVA Iovance Biotherapeutics - 12/08/22 Goldman Sachs
- Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs
- 11/21/22 JMP Securities
- Iovance Biotherapeutics price target lowered to $21 from $25 at JMP Securities
- 11/20/22 Piper Sandler
- Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
- 11/18/22 Chardan
- Iovance Biotherapeutics price target lowered to $29 from $30 at Chardan
- $266.37 /
+4.545 (+1.74%) - 12/08/22
- RH narrow FY22 revenue growth view to down 4.5% to down 3.5%
- 12/08/22
- RH reports Q3 EPS $5.67, consensus $4.70
- 09/08/22
- RH sees Q3 revenue down 18% to down 15%
- 12/08/22
- Phreesia raises FY23 revenue to 'at least $278M', consensus $274.3M
- 12/08/22
- Phreesia reports Q3 EPS (76c), consensus (61c)
- 09/07/22
- Phreesia affirms FY25 revenue target of $500M
- 09/07/22
- Phreesia narrows FY23 revenue view to $273M-$275M from $271M-$275M
- 12/08/22
- Vail Resorts reports Q1 EPS ($3.40), consensus ($3.43)
- 09/29/22
- Vail Resorts reports Q4 EPS ($2.70), consensus ($2.92)
- 06/09/22
- Vail Resorts reports Q3 EPS $9.18, consensus $9.06
- 06/09/22
- Notable companies reporting after market close
- 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
JAZZ Jazz Pharmaceuticals - 11/09/22
- Jazz Pharmaceuticals raises FY22 EPS view to $17.20-$17.85 from $16.70-$17.70
- 11/09/22
- Jazz Pharmaceuticals reports Q3 adjusted EPS $5.17, consensus $4.66
- 08/03/22
- Jazz Pharmaceuticals backs FY22 revenue view $3.5B-$3.7B, consensus $3.6B
- 08/03/22
- Jazz Pharmaceuticals backs FY22 non-GAAP EPS view $16.70-$17.70
IOVA Iovance Biotherapeutics - 11/03/22
- Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c)
- 08/04/22
- Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c)
- 12/08/22
- DocuSign sees FY23 revenue $2.493B-$2.497B, consensus $2.49B
- 12/08/22
- DocuSign sees Q4 revenue $637M-$641M, consensus $640.51M
- 12/08/22
- DocuSign reports Q3 adjusted EPS 57c, consensus 42c
- 12/08/22
- Notable companies reporting after market close
- 12/08/22
- Torrid cuts FY22 revenue view to $1.244B-$1.259B from $1.26B-$1.3B
- 12/08/22
- Torrid sees Q4 revenue $285M-$300M, consensus $311.99M
- 12/08/22
- Torrid reports Q3 EPS 7c, consensus 12c
- 09/07/22
- Torrid cuts FY22 revenue view to $1.26B-$1.3B from $1.3B-$1.365B
- 12/08/22
- Chewy raises FY22 revenue view to $10.02B-$10.04B from $9.9B-$10B
- 12/08/22
- Chewy sees Q4 revenue $2.63B-$2.65B, consensus $2.64B
- 12/08/22
- Chewy reports Q3 revenue $2.53B, consensus $2.46B
- 11/17/22
- Bath & Body Works sees FY22 sales down mid single digits vs. 2021
- 11/17/22
- Bath & Body Works sees Q4 sales down mid single to low double digits vs. 2021
- 11/16/22
- Bath & Body Works raises FY22 EPS view to $3.00-$3.20 from $2.70-$3.00
- 11/16/22
- Bath & Body Works sees Q4 EPS $1.45-$1.65, consensus $1.55
- $531.27 /
+12.72 (+2.45%) - 12/08/22
- Broadcom sees Q1 revenue $8.9B, consensus $8.79B
- 12/08/22
- Broadcom reports Q4 EPS $10.45, consensus $10.28
- 09/01/22
- Broadcom sees Q4 revenue $8.9B, consensus $8.73B
- 09/30/22
- Peloton tells Bloomberg resolved dispute with Lululemon over athletic wear
- 09/29/22
- Peloton suit against Lululemon thrown out by court, Bloomberg reports
- 09/29/22
- Lululemon wins dismissal of patent suit by Peloton, Bloomberg reports
- 08/17/22
- Lululemon D.C. workers withdraw bid for union vote, Bloomberg reports
JAZZ Jazz Pharmaceuticals - 11/18/22
- Judge rules Jazz Pharmaceuticals must delist Xyrem patent, Bloomberg reports
- 07/01/22
- DocuSign challenges could lead to activist or suitor, The Deal says
- $531.27 /
+12.72 (+2.45%) - 10/16/22
- Broadcom banks on early EU approval of $61B VMware deal, Reuters says
- 06/23/22
- Broadcom $69B VMware deal set for lengthy EU antitrust probe, FT says
- $266.37 /
+4.545 (+1.74%) - 11/21/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/09/22
- What You Missed On Wall Street On Friday
- 09/09/22
- What You Missed On Wall Street This Morning
- 09/07/22
- Fly Intel: After-Hours Movers
- 07/15/22
- Sell these stocks now, proven algorithm says
- 09/29/22
- What You Missed On Wall Street On Thursday
- 09/29/22
- What You Missed On Wall Street This Morning
- 09/29/22
- Fly Intel: Pre-market Movers
- 09/28/22
- Fly Intel: After-Hours Movers
- 10/13/22
- What You Missed On Wall Street On Thursday
- 10/13/22
- What You Missed On Wall Street This Morning
- 10/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/11/22
- What You Missed On Wall Street On Tuesday
JAZZ Jazz Pharmaceuticals - 11/02/22
- Biotech Alert: Searches spiking for these stocks today
- 10/19/22
- What You Missed On Wall Street On Wednesday
- 10/19/22
- What You Missed On Wall Street This Morning
IOVA Iovance Biotherapeutics - 12/07/22
- Biotech Alert: Searches spiking for these stocks today
- 12/05/22
- What You Missed On Wall Street On Monday
- 12/05/22
- Fly Intel: Pre-market Movers
- 11/30/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/03/22
- What You Missed On Wall Street On Monday
- 10/03/22
- What You Missed On Wall Street This Morning
- 07/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/07/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/07/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/16/22
- Short Report: Chewy bears return just as stock finds support
- 11/17/22
- What You Missed On Wall Street On Thursday
- 11/17/22
- What You Missed On Wall Street This Morning
- 11/16/22
- Fly Intel: After-Hours Movers
- 08/18/22
- What You Missed On Wall Street On Thursday
- $531.27 /
+12.72 (+2.45%) - 11/16/22
- Here's what Wall Street experts are saying about Nvidia ahead of earnings
- 09/02/22
- What You Missed On Wall Street On Friday
- 09/02/22
- What You Missed On Wall Street This Morning
- 09/02/22
- Fly Intel: Pre-market Movers
- $266.37 /
+4.545 (+1.74%) - 12/08/22
- Restoration Hardware options imply 7.8% move in share price post-earnings
- 10/24/22
- Restoration Hardware put volume heavy and directionally bearish
- 09/08/22
- Restoration Hardware options imply 7.3% move in share price post-earnings
- 09/06/22
- Restoration Hardware call volume above normal and directionally bullish
- 12/08/22
- Lululemon options imply 6.9% move in share price post-earnings
- 09/30/22
- Unusually active option classes on open September 30th
- 09/01/22
- Lululemon options imply 5.0% move in share price post-earnings
- 08/09/22
- Lululemon put volume heavy and directionally bearish
IOVA Iovance Biotherapeutics - 06/27/22
- Iovance Biotherapeutics call volume above normal and directionally bullish
- 12/08/22
- DocuSign options imply 14.3% move in share price post-earnings
- 12/05/22
- DocuSign put volume heavy and directionally bearish
- 09/08/22
- DocuSign options imply 13.1% move in share price post-earnings
- 09/01/22
- DocuSign put volume heavy and directionally bearish
- 09/07/22
- Torrid Holdings options imply 12.6% move in share price post-earnings
- 12/08/22
- Chewy options imply 11.4% move in share price post-earnings
- 12/07/22
- Chewy put volume heavy and directionally bearish
- 11/28/22
- Chewy put volume heavy and directionally bearish
- 11/04/22
- Chewy put volume heavy and directionally bearish
- 12/02/22
- Bath & Body Works call volume above normal and directionally bullish
- 11/18/22
- Early notable gainers among liquid option names on November 18th
- 11/17/22
- Early notable gainers among liquid option names on November 17th
- 11/16/22
- Bath & Body Works options imply 10.3% move in share price post-earnings
- $531.27 /
+12.72 (+2.45%) - 12/08/22
- Broadcom options imply 4.1% move in share price post-earnings
- 11/10/22
- Unusually active option classes on open November 10th
- 09/02/22
- Early notable gainers among liquid option names on September 2nd
- 09/01/22
- Broadcom options imply 3.4% move in share price post-earnings
|
|
Downgrade
|
Goldman Sachs analyst… Goldman Sachs analyst Madhu Kumar downgraded Iovance Biotherapeutics to Neutral from Buy with a price target of $6, down from $20. The analyst is citing concerns around the clinical, regulatory, financing, competitive, and commercial path for the company's lead asset, tumor-infiltrating lymphocyte drug lifileucel in metastatic melanoma, MM. While lifileucel has shown "promising efficacy" in post-PD-1 MM, he sees the potential for "multiple headwinds" for the drug's commercialization, Kumar tells investors in a research note. The analyst adds that he also sees potential for lifileucel in post-PD-1/chemo cervical cancer and LN-145 in post-PD-1 non-small cell lung cancer, but there is a lack of a "defined catalyst path" for these programs. ShowHide Related Items >><< IOVA Iovance Biotherapeutics - 12/02/22
- Iovance rallies after director buys $65M worth of shares
- 11/18/22
- Iovance Biotherapeutics: BLA for lifileucel expected to be completed in 1Q23
- 11/10/22
- Iovance Biotherapeutics announces updated clinical data for lifileucel
- 11/07/22
- Iovance Biotherapeutics announces updated clinical data for Lifileucel
IOVA Iovance Biotherapeutics - 11/21/22 JMP Securities
- Iovance Biotherapeutics price target lowered to $21 from $25 at JMP Securities
- 11/20/22 Piper Sandler
- Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
- 11/18/22 Chardan
- Iovance Biotherapeutics price target lowered to $29 from $30 at Chardan
- 11/18/22 Oppenheimer
- Iovance price target lowered to $25 from $27 at Oppenheimer
IOVA Iovance Biotherapeutics - 11/03/22
- Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c)
- 08/04/22
- Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c)
IOVA Iovance Biotherapeutics - 12/07/22
- Biotech Alert: Searches spiking for these stocks today
- 12/05/22
- What You Missed On Wall Street On Monday
- 12/05/22
- Fly Intel: Pre-market Movers
IOVA Iovance Biotherapeutics - 06/27/22
- Iovance Biotherapeutics call volume above normal and directionally bullish
|
|
On The Fly
| ShowHide Related Items >><< - 12/05/22
- Protalix, Chiesi Global Rare Diseases announce FDA acceptance of PRX-102 BLA
- 11/14/22
- Protalix, Chiesi Global Rare Diseases resubmits PRX-102 BLA to FDA
ONCT Oncternal Therapeutics - 10/03/22
- Oncternal Therapeutics receives 'Study May Proceed' letter from FDA for ONCT-808
- 09/27/22
- Oncternal initiates global registrational Phase 3 study of zilovertamab
- 07/14/22
- Oncternal Therapeutics enters conical trial collaboration with Pharmacyclics
- 06/10/22
- Oncternal Therapeutics presents rationale, plans for Phase 3 ZILO-301 trial
- 12/05/22
- Nymox submits MAA in Europe for NYMOZARFEX
- 09/13/22
- Nymox in process of preparing FDA requested documentation for NDA resubmission
- 07/15/22
- Nymox says business plans continuing to be developed, on track
- 07/14/22
- Nymox receives deficiency letter from NASDAQ
IOVA Iovance Biotherapeutics - 12/02/22
- Iovance rallies after director buys $65M worth of shares
- 11/18/22
- Iovance Biotherapeutics: BLA for lifileucel expected to be completed in 1Q23
- 11/10/22
- Iovance Biotherapeutics announces updated clinical data for lifileucel
- 11/07/22
- Iovance Biotherapeutics announces updated clinical data for Lifileucel
- 11/16/22
- Avid Bioservices appoints Lukash as vice president, people
- 10/10/22
- Tomi to install custom engineered iHP System in Avid Bioservices facility
- 09/22/22
- Avid Bioservices appoints Alston as VP, operations
- 09/01/22
- Avid names Prem Patel as VP, process development, mammalian cell business
ONCT Oncternal Therapeutics - 08/10/22 H.C. Wainwright
- Oncternal Therapeutics price target lowered to $7 from $8 at H.C. Wainwright
- 05/27/22 Northland
- Oncternal updated interim data should be catalyst for shares, says Northland
- 05/10/22 Maxim
- Oncternal Therapeutics initiated with a Buy at Maxim
- 02/24/22 BTIG
- Oncternal Therapeutics initiated with a Buy at BTIG
IOVA Iovance Biotherapeutics - 11/21/22 JMP Securities
- Iovance Biotherapeutics price target lowered to $21 from $25 at JMP Securities
- 11/20/22 Piper Sandler
- Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
- 11/18/22 Chardan
- Iovance Biotherapeutics price target lowered to $29 from $30 at Chardan
- 11/18/22 Oppenheimer
- Iovance price target lowered to $25 from $27 at Oppenheimer
- 12/07/22 Craig-Hallum
- Avid Bioservices price target lowered to $25 from $30 at Craig-Hallum
- 06/30/22 RBC Capital
- Avid Bioservices price target lowered to $22 from $32 at RBC Capital
- 03/09/22 Craig-Hallum
- Avid Bioservices price target lowered to $30 from $35 at Craig-Hallum
- 12/08/21 RBC Capital
- Avid Bioservices price target raised to $32 from $27 at RBC Capital
ONCT Oncternal Therapeutics - 11/03/22
- Oncternal Therapeutics reports Q3 EPS (21c), consensus (24c)
- 08/09/22
- Oncternal Therapeutics reports Q2 EPS (23c), consensus (23c)
IOVA Iovance Biotherapeutics - 11/03/22
- Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c)
- 08/04/22
- Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c)
- 12/06/22
- Avid Bioservices raises FY23 revenue view to $145M-$150M from $140M-$145M
- 12/06/22
- Avid Bioservices reports Q2 EPS (2c), consensus 0c
- 09/06/22
- Avid Bioservices reports Q1 EPS 2c vs. 10c last year
- 06/29/22
- Avid Bioservices reports Q4 EPS $1.65 vs. (4c) YoY
- 12/07/22
- Biotech Alert: Searches spiking for these stocks today
IOVA Iovance Biotherapeutics - 12/05/22
- What You Missed On Wall Street On Monday
- 12/05/22
- Fly Intel: Pre-market Movers
- 06/29/22
- Fly Intel: After-Hours Movers
IOVA Iovance Biotherapeutics - 06/27/22
- Iovance Biotherapeutics call volume above normal and directionally bullish
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - $106.80 /
-3.035 (-2.76%) - 11/07/22
- Exxon Mobil, partners make new discovery on Angola Block 15
- 10/28/22
- Exxon Mobil reports Q3 cash flow from operating activities $24.4B
- 12/05/22
- VF Corp. CEO Steve Rendle retires, Benno Dorer named as interim CEO
- 11/14/22
- VF Corp. releases FY22 annual profile on IDEA
- 10/26/22
- VF Corp. sees FY23 North Face revenue up at least 12%
- 09/28/22
- VF Corp. introduces FY27 targets at investor day
- 11/09/22
- Veru announces update on FDA AdCom meeting on Sabizabulin as COVID treatment
- 11/09/22
- Veru trading halted, news pending
- 11/07/22
- Veru jumps 32% after FDA posts briefing documents for meeting of advisors
- 10/24/22
- Veru announces late-breaker oral presentation of sabizabulin treatment
USO United States Oil Fund - 06/14/22
- Freeport LNG issues update on incident at liquefaction plant on June 8
- 11/30/22
- United Airlines invests in Natron Energy
- 11/20/22
- Fly Intel: Top five weekend stock stories
- 11/15/22
- United Airlines investing in biofuel refinery
- 11/11/22
- Clear Secure announces United Airlines customers can enroll in Clear through app
- 09/16/22
- TotalEnergies reports exploration and production sharing agreement for Block 11
- 08/23/22
- Sealed Air invests $9M in solar farm powering California manufacturing facility
- $182.42 /
-12.43 (-6.38%) - 12/02/22
- Ford reports November U.S. sales down 7.8% to 146,364 vehicles
- 11/28/22
- Musk says Apple 'threatened to withhold Twitter' from App Store
- 11/25/22
- Tesla to recall just over 80,000 vehicles in China
- 11/17/22
- EU passenger car registrations up 12.2% in October
- 12/05/22
- SL Green Realty reduces annual dividend to $3.25 per share
- 12/05/22
- SL Green Realty, Chef Daniel Boulud announces food concepts at One Madison
- 12/05/22
- Roc Nation joins SL Green, Caesars as partner in Times Square gaming bid
- 10/20/22
- SL Green Realty, Caesars pursue gaming license for Times Square
- 11/28/22
- Silvergate Capital says BlockFi deposit relationship limited to less than $20M
- 11/23/22
- block.one reports 7.46% passive stake in Silvergate Capital
- 11/17/22
- Silvergate Capital falls -11.4%
- 11/17/22
- Silvergate Capital falls -10.4%
- 12/05/22
- KBR awarded contract to design offshore energy storage for CrossWind
- 11/28/22
- Shell to acquire RNG producer Nature Energy for nearly $2B
- 11/27/22
- Fly Intel: Top five weekend stock stories
- 11/28/22
- Starbucks exec Conway sells 15,320 common shares
- 11/03/22
- Starbucks says retention has increased for baristas
- 11/03/22
- Starbucks says 'confident' in long term growth opportunity in China
- 11/03/22
- Starbucks reports Q4 global SSS up 7%
- 12/05/22
- Salisbury Bancorp trading resumes
- 12/05/22
- Salisbury Bancorp trading halted, news pending
- 07/01/22
- Salisbury Bancorp completes two-for-one forward stock split
- $113.98 /
+5.145 (+4.73%) - 12/01/22
- SAIC awarded maximum $151M Transportation Command contract
- 11/22/22
- SAIC received about $950M in space, intelligence contract awards in Q3
- 11/14/22
- SAIC awarded $757M U.S. Army contract for software management services
- 09/27/22
- SAIC gets $170M NASA contract for IV&V of space systems and software
- 12/05/22
- Rackspace under pressure following 'security incident' across some servers
- 11/30/22
- Onica Rackspace Technology achieves Service Delivery designation for AWS Glue
- 11/17/22
- Rackspace Technology appoints Bobby Molu as CFO
- 11/17/22
- ADGM, Rackspace Technology enter pact for strategic technology initiative
- 11/14/22
- Elliott made Triple Flag Precious Metals top holding during Q3
- 10/28/22
- Pinterest rises 14.4%
- 10/27/22
- Pinterest jumps 14% to $24.89 after Q3 results beat estimates
- 10/27/22
- Pinterest sees FY non-GAAP operating expenses up 35% y/y
- 12/01/22
- Nutriband receives notice of issuance from CIPO for AVERSA patent
- 11/08/22
- Nutriband supports newly published CDC opioid prescribing guidelines
- 10/27/22
- Nutriband signs exclusive manufacturing agreement with Fleur Marche
- 10/26/22
- Nutriband's 4P Therapeutics conducts Phase 1b study for Sorrento Therapeutics
- 11/15/22
- Nike raises quarterly dividend 11% to 34c per share
- 11/15/22
- Albemarle names Sean O'Hollaren as chief external affairs officer
- 09/29/22
- Nike sees Q2 revenue up low double digits, gross margins to decline 350-400bps
- 09/29/22
- Nike CFO says FY23 gross margins to decline 200-250bps in FY23
- 12/05/22
- NBT Bancorp, Salisbury Bancorp announces agreement to merge
- 12/01/22
- VICI to acquire remaining 49.9% interest in MGM Grand, Mandalay from BREIT
- 12/01/22
- VICI Properties to buy 49.9% interest in MGM joint venture from BREIT for $1.27B
- 12/01/22
- Macau reports November casino revenue down 55.6% to 3.0B patacas
- 11/29/22
- Nevada reports October statewide gaming win up 4.83% to $1.28B
- 12/05/22
- Yumanity declares special dividend related to asset sale, merger with Kineta
- 12/01/22
- Cidara Therapeutics announces issuance of first U.S. patent for CD388
IOVA Iovance Biotherapeutics - 12/02/22
- Iovance rallies after director buys $65M worth of shares
- 11/18/22
- Iovance Biotherapeutics: BLA for lifileucel expected to be completed in 1Q23
- 11/10/22
- Iovance Biotherapeutics announces updated clinical data for lifileucel
- 11/07/22
- Iovance Biotherapeutics announces updated clinical data for Lifileucel
HZNP Horizon Therapeutics - 12/05/22
- J&J says 'it does not intent to make offer' for Horizon Therapeutics
- 12/02/22
- Sanofi says any offer for Horizon Therapeutics, if made, to be 'solely in cash'
- 11/29/22
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- 12/01/22
- Farfetch falls -20.2%
- 11/18/22
- Farfetch falls -14.1%
- 11/18/22
- Farfetch falls -12.0%
- 10/21/22
- Farfetch announces first cohort of start-ups for Dream Assembly Base Camp
ENLV Enlivex Therapeutics - 11/28/22
- Enlivex Therapeutics receives FDA clearance for Allocetra IND
- 11/15/22
- Enlivex announces dosing of first patient in Phase I/II trial of Allocetra
- 09/12/22
- Enlivex announces new preclinical data in murine mesothelioma model
- 09/06/22
- Enlivex Therapeutics receives notice of allowance for patent related to Alocetra
- 11/21/22
- Domino's Pizza CEO: Hiring is back to 2019 levels in stores
- 11/21/22
- Domino's Pizza to roll out nationwide fleet of 800 Chevy Bolt EVs
- 11/16/22
- Restaurant Brands appoints Patrick Doyle as executive chairman
- 11/15/22
- Pershing Square exits Domino's, boosts stake in Canadian Pacific in Q3
- 12/02/22
- Cushman & Wakefield to replace Diebold in S&P 600 at open on 12/19
- 09/06/22
- Finacity, ING Belgium facilitate increase of ARS program for Cushman & Wakefield
- 08/30/22
- Cushman & Wakefield announces Payman Sadegh joins as Chief Data Officer
- 08/25/22
- Cushman & Wakefield signs preferred supplier agreement with Blink Charging
- 11/17/22
- Chevron to acquire full ownership of Beyond6 CNG fueling network
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 11/10/22
- Chevron, Mitsui O.S.K. to explore transportation of 2.5M tons per annum of CO2
- 11/21/22
- CVS Health board approves 2022 Repurchase Program for $10B of shares
- 11/16/22
- Oak Street Health turns green, up 3% in afternoon trading
- 11/02/22
- CVS Health expects FY23 cash flow 'similar' to FY22
- 12/02/22
- Credit Suisse rallies after Chairman says outflows 'basically stopped'
- 11/23/22
- Credit Suisse sees likely loss for Wealth Management in Q4
- 11/23/22
- Credit Suisse sees 'substantial' loss of up to CHF 1.5B in Q4
- 11/23/22
- Credit Suisse confirms capital ratio guidance from October 27
- $133.87 /
-10.695 (-7.40%) - 12/05/22
- Frontdoor CFO Brian Turcotte to step down, Jessica Ross to succeed
- 11/30/22
- Salesforce CEO: Departure of co-CEO Bret Taylor 'a gut punch'
- 11/30/22
- Salesforce falls 7% to $150 after Q3 results, resignation of co-CEO Bret Taylor
- 11/30/22
- Salesforce's Bret Taylor to step down as Vice Chair and co-CEO
- $119.37 /
-2.385 (-1.96%) - 11/29/22
- ConocoPhillips, QatarEnergy sign two deals to supply long-term LNG to Germany
- 11/22/22
- Sempra Energy subsidiary and ConocoPhillips execute SPA for 5Mtpa of LNG
- 11/15/22
- TotalEnergies completes acquisition of Hess 8.16% interest Waha concession
- 11/07/22
- Aris Water Solutions enters strategic agreement with Chevron, ConocoPhillips
- 11/23/22
- EC proposes new EU instrument to blunt excessive gas price spikes
- 11/01/22
- BP sees 2022 upstream production slightly higher than 2021
- 11/01/22
- BP sees Q4 upstream production on a reported basis slightly lower than Q3
- 11/01/22
- BP expects oil prices to remain elevated in Q4
- 12/04/22
- Fly Intel: Top five weekend stock stories
- 12/02/22
- Coinbase says Apple blocked last app release on NFTs
- 11/30/22
- Musk says Apple CEO never considered removing Twitter from App Store
- $133.87 /
-10.695 (-7.40%) - 12/05/22 KeyBanc
- Veeva price target lowered to $210 from $220 at KeyBanc
- 12/05/22 Credit Suisse
- Salesforce price target lowered to $225 from $250 at Credit Suisse
- 12/05/22 Citi
- Salesforce price target lowered to $164 from $170 at Citi
- 12/02/22 Morgan Stanley
- Veeva assumed with an Equal Weight at Morgan Stanley
IOVA Iovance Biotherapeutics - 11/21/22 JMP Securities
- Iovance Biotherapeutics price target lowered to $21 from $25 at JMP Securities
- 11/20/22 Piper Sandler
- Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
- 11/18/22 Chardan
- Iovance Biotherapeutics price target lowered to $29 from $30 at Chardan
- 11/18/22 Oppenheimer
- Iovance price target lowered to $25 from $27 at Oppenheimer
- 12/02/22 JPMorgan
- BP price target raised to 560 GBp from 530 GBp at JPMorgan
- 11/22/22 Citi
- BP upgraded to Buy from Neutral at Citi
- 11/14/22 Wells Fargo
- Archaea Energy downgraded to Equal Weight from Overweight at Wells Fargo
- 11/11/22 Piper Sandler
- BP price target raised to $40 from $37 at Piper Sandler
- $119.37 /
-2.385 (-1.96%) - 11/22/22 Citi
- ConocoPhillips price target raised to $160 from $132 at Citi
- 11/21/22 Argus
- ConocoPhillips price target raised to $150 from $125 at Argus
- 11/21/22 Societe Generale
- ConocoPhillips downgraded to Sell on valuation at Societe Generale
- 11/21/22 Societe Generale
- ConocoPhillips downgraded to Sell from Hold at Societe Generale
- 12/02/22 JPMorgan
- Shell price target raised to 2,950 GBp from 2,900 GBp at JPMorgan
- 11/11/22 Piper Sandler
- Shell price target raised to $71 from $65 at Piper Sandler
- 11/08/22 Morgan Stanley
- Shell price target raised to 2,922 GBp from 2,860 GBp at Morgan Stanley
- 11/06/22 Goldman Sachs
- Shell downgraded to Neutral from Buy at Goldman Sachs
- 12/02/22 JPMorgan
- TotalEnergies price target raised to EUR 68 from EUR 66 at JPMorgan
- 12/02/22 JPMorgan
- TotalEnergies added to Analyst Focus List at JPMorgan
- 11/11/22 Piper Sandler
- TotalEnergies price target raised to $66 from $58 at Piper Sandler
- 11/08/22 Morgan Stanley
- TotalEnergies price target raised to EUR 65 from EUR 58 at Morgan Stanley
- $106.80 /
-3.035 (-2.76%) - 11/22/22 Citi
- Exxon Mobil price target raised to $110 from $98 at Citi
- 11/11/22 Piper Sandler
- Exxon Mobil price target raised to $131 from $113 at Piper Sandler
- 11/01/22 Exane BNP Paribas
- Exxon Mobil upgraded to Neutral from Underperform at Exane BNP Paribas
- 10/31/22 Truist
- Exxon Mobil price target raised to $114 from $111 at Truist
- 11/22/22 Citi
- Chevron price target raised to $180 from $155 at Citi
- 11/11/22 Piper Sandler
- Chevron price target raised to $206 from $186 at Piper Sandler
- 10/31/22 Cowen
- Chevron price target raised to $185 from $160 at Cowen
- 10/24/22 HSBC
- Chevron downgraded to Hold from Buy at HSBC
USO United States Oil Fund - 12/06/22 Baird
- VF Corp. removed from bullish Fresh Pick at Baird
- 12/05/22 Deutsche Bank
- VF Corp. risk/reward favorable with bar reset, says Deutsche Bank
- 12/05/22 Credit Suisse
- Credit Suisse downgrades VF Corp. after 'abrupt' CEO transition
- 12/05/22 Credit Suisse
- VF Corp. downgraded to Neutral from Outperform at Credit Suisse
- 12/06/22 Janney Montgomery Scott
- Salisbury Bancorp downgraded to Neutral at Janney after NBT Bancorp deal
- 01/09/22 Keefe Bruyette
- NBT Bancorp assumed with a Market Perform at Keefe Bruyette
- 12/06/22 Janney Montgomery Scott
- Salisbury Bancorp downgraded to Neutral from Buy at Janney Montgomery Scott
- $182.42 /
-12.43 (-6.38%) - 12/05/22 Piper Sandler
- If Tesla cuts production in China, it won't be due to competition, says Piper
- 11/29/22 Bernstein
- Tesla risk/reward 'more balanced' after 48% drop, says Bernstein
- 11/28/22 Jefferies
- XPeng downgraded to Underperform at Jefferies ahead of 'challenging year'
- 11/23/22 Morgan Stanley
- Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
- 12/05/22 Wedbush
- Apple shift out of China will not be easy, says Wedbush
- 12/02/22 Morgan Stanley
- Morgan Stanley sees December quarter App Store forecast as 'conservative'
- 12/01/22 Piper Sandler
- Apple estimates lowered on shutdowns in Zhengzhou at Piper Sandler
- 11/30/22 Wedbush
- China lockdown ends in iPhone city, heavy lifting ahead for Apple, says Wedbush
- 12/05/22 Deutsche Bank
- Starbucks downgraded to Hold from Buy at Deutsche Bank
- 11/04/22 Evercore ISI
- Starbucks price target raised to $97 from $95 at Evercore ISI
- 11/04/22 Citi
- Starbucks price target raised to $93 from $90 at Citi
- 11/04/22 Wedbush
- Starbucks price target raised to $96 from $92 at Wedbush
- 12/05/22 BTIG
- Domino's Pizza upgraded to Buy from Neutral at BTIG
- 11/30/22 Citi
- Domino's Pizza price target raised to $441 from $407 at Citi
- 11/18/22 Northcoast
- Domino's Pizza upgraded to Buy from Neutral at Northcoast
- 10/14/22 BMO Capital
- Domino's Pizza price target lowered to $400 from $430 at BMO Capital
- 12/06/22 Argus
- United Airlines upgraded to Buy from Hold at Argus
- 12/05/22 Morgan Stanley
- United Airlines upgraded to Overweight from Equal Weight at Morgan Stanley
- 10/25/22 Cowen
- Mesa Air price target lowered to $1.50 from $4.00 at Cowen
- 10/21/22 Citi
- United Airlines price target raised to $65 from $56 at Citi
- 12/05/22 Truist
- MGM Resorts upgraded to Buy at Truist amid returning activity at the Strip
- 12/05/22 Truist
- MGM Resorts upgraded to Buy from Hold at Truist
- 11/28/22 Jefferies
- Macau concession renewals removes overhang for incumbents, says Jefferies
- 11/28/22 JPMorgan
- DraftKings downgraded to Underweight from Neutral at JPMorgan
- 12/05/22 Morgan Stanley
- Silvergate Capital downgraded to Underweight from Equal Weight at Morgan Stanley
- 11/29/22 Keefe Bruyette
- Silvergate exposure to BlockFi 'very modest,' says Keefe Bruyette
- 11/25/22 Morgan Stanley
- Silvergate Capital price target lowered to $24 from $37 at Morgan Stanley
- 11/22/22 BTIG
- Silvergate Capital price target lowered to $51 from $135 at BTIG
- 11/21/22 Citi
- Rackspace Technology price target lowered to $5 from $7 at Citi
- 11/10/22 Deutsche Bank
- Rackspace Technology price target lowered to $5 from $6 at Deutsche Bank
- 10/11/22 Evercore ISI
- Rackspace Technology downgraded to In Line at Evercore ISI on 2023 risks
- 10/11/22 Evercore ISI
- Rackspace Technology downgraded to In Line from Outperform at Evercore ISI
- 11/23/22 Morgan Stanley
- CVS Health assumed with an Overweight at Morgan Stanley
- 11/21/22 Credit Suisse
- CVS Health price target raised to $125 from $117 at Credit Suisse
- 11/06/22 Raymond James
- CVS Health price target lowered to $115 from $120 at Raymond James
- 11/02/22 B. Riley
- B. Riley downgrades Semler Scientific on risk from Signify buyout
- 10/31/22 Citi
- Pinterest price target raised to $26 from $25 at Citi
- 10/28/22 Stifel
- Pinterest 'a rare bright spot thus far through earnings,' says Stifel
- 10/28/22 Barclays
- Pinterest price target raised to $25 from $23 at Barclays
- 10/28/22 Piper Sandler
- Pinterest price target raised to $25 from $23 at Piper Sandler
- 11/22/22 Cowen
- Nike price target raised to $118 from $114 at Cowen
- 11/07/22 Stifel
- Deckers Brands price target raised to $416 from $390 at Stifel
- 10/13/22 Raymond James
- Nike initiated with an Outperform at Raymond James
- 10/12/22 Raymond James
- Nike initiated with an Outperform at Raymond James
- 12/01/22 JPMorgan
- Credit Suisse price target lowered to CHF 3.80 from CHF 5.50 at JPMorgan
- 11/07/22 AlphaValue/Baader
- Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
- 10/28/22 JPMorgan
- Credit Suisse price target lowered to CHF 5.50 from CHF 6 at JPMorgan
- 10/06/22 JPMorgan
- Credit Suisse upgraded to Neutral from Underweight at JPMorgan
- 07/22/22 Raymond James
- Cushman & Wakefield removed from Analyst Current Favorites list at Raymond James
- 04/21/22 Citi
- Cushman & Wakefield price target lowered to $21 from $23 at Citi
- 04/05/22 Goldman Sachs
- Cushman & Wakefield initiated with a Buy at Goldman Sachs
- 03/10/22 Wolfe Research
- Cushman & Wakefield price target lowered to $28 from $44 at Wolfe Research
HZNP Horizon Therapeutics - 12/01/22 Jefferies
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- 11/30/22 Cowen
- Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
- 11/30/22 Wells Fargo
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- 11/01/22 H.C. Wainwright
- Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
- 12/01/22 Morgan Stanley
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
- 11/29/22 Craig-Hallum
- Craig-Hallum sees potential for competing Apollo Endosurgery bids
- 12/05/22 Cowen
- Farfetch price target lowered to $8 from $11 at Cowen
- 12/02/22 Wells Fargo
- Farfetch price target lowered to $18 from $25 at Wells Fargo
- 12/02/22 JPMorgan
- Farfetch selloff on financial outlook overdone, says JPMorgan
- 12/02/22 BTIG
- Farfetch price target lowered to $10 from $13 at BTIG
- $113.98 /
+5.145 (+4.73%) - 12/06/22 Truist
- SAIC price target raised to $120 from $105 at Truist
- 12/06/22 Wells Fargo
- SAIC price target raised to $121 from $99 at Wells Fargo
- 12/05/22 Stifel
- SAIC price target raised to $110 from $99 at Stifel
- 11/17/22 Jefferies
- SAIC downgraded to Hold at Jefferies on lower growth than peers
- 11/10/22 H.C. Wainwright
- Veru price target lowered to $21 from $24 at H.C. Wainwright
- 09/20/22 Oppenheimer
- Oppenheimer optimism for Veru's sabizabulin EUA remains 'unchanged'
- 09/08/22 Oppenheimer
- Oppenheimer remains bullish on Veru, optimism for EUA unchanged
- 08/11/22 Cantor Fitzgerald
- Veru price target raised to $30 from $24 at Cantor Fitzgerald
- 12/06/22 Scotiabank
- Scotiabank downgrades SL Green with balance sheet looking 'stressed'
- 12/06/22 BMO Capital
- SL Green Realty downgraded to Market Perform from Outperform at BMO Capital
- 12/06/22 Scotiabank
- SL Green Realty downgraded to Underperform from Sector Perform at Scotiabank
- 11/23/22 Morgan Stanley
- SL Green Realty price target lowered to $38 from $44 at Morgan Stanley
ENLV Enlivex Therapeutics - 05/02/22 H.C. Wainwright
- Enlivex Therapeutics price target lowered to $15 from $33 at H.C. Wainwright
- $106.80 /
-3.035 (-2.76%) - 10/28/22
- Exxon Mobil reports Q3 adjusted EPS $4.45, consensus $3.79
- 10/27/22
- Notable companies reporting before tomorrow's open
- 07/29/22
- Exxon Mobil reports Q2 adjusted EPS $4.14, consensus $3.74
- 12/05/22
- VF Corp. cuts FY23 adjusted EPS view to $2.00-$2.20 from $2.40-$2.50
- 10/26/22
- VF Corp. cuts FY23 adjusted EPS $2.40-$2.50 from $2.60-$2.70
- 10/26/22
- VF Corp. reports Q2 adjusted EPS 73c, consensus 73c
- 10/26/22
- Notable companies reporting after market close
- 12/05/22
- Veru reports Q4 EPS (51c), consensus (30c)
- 08/11/22
- Veru reports Q3 EPS (28c), consensus (18c)
- 10/18/22
- United Airlines sees Q4 adjusted EPS $2.00-$2.25, consensus 98c
- 10/18/22
- United Airlines reports Q3 adjusted EPS $2.81, consensus $2.27
- 10/18/22
- Notable companies reporting after market close
- 07/20/22
- United Airlines reports Q2 EPS $1.43, consensus $1.94
- $182.42 /
-12.43 (-6.38%) - 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 12/05/22
- SL Green Realty affirms FY22 FFO per share of $6.70-$7.00, consensus $6.69
- 12/05/22
- SL Green Realty sees FY23 FFO per share of $5.30-$5.60, consensus $6.12
- 10/19/22
- SL Green Realty reports Q3 FFO $1.66, consensus $1.64
- 07/20/22
- SL Green Realty reports Q2 FFO $1.87, consensus $1.69
- 10/18/22
- Silvergate Capital reports Q3 EPS $1.28, consensus $1.38
- 07/19/22
- Silvergate Capital reports Q2 EPS $1.13, consensus 84c
- 07/18/22
- Notable companies reporting before tomorrow's open
- 10/27/22
- Shell reports Q3 adjusted EPS $1.30 vs. 53c last year
- 07/28/22
- Shell reports Q2 adjusted EPS $2.42 vs. 71c last year
- 11/03/22
- Starbucks sees FY23 adjusted EPS growth at low end of 15%-20% range
- 11/03/22
- Starbucks reports Q4 adjusted EPS 81c, consensus 72c
- 11/03/22
- Notable companies reporting after market close
- 09/13/22
- Starbucks increases CapEx view to $2.5B-$3B annually from FY23-FY25
- $113.98 /
+5.145 (+4.73%) - 12/05/22
- SAIC raises FY23 adjusted EPS view to $7.05-$7.20 from $7.00-$7.20
- 12/05/22
- SAIC reports Q3 EPS $1.90, consensus $1.74
- 09/01/22
- SAIC narrows FY23 EPS guidance $7.00-$7.20 from $6.90-$7.20
- 09/01/22
- SAIC reports Q2 adjusted EPS $1.75 vs $1.97 last year
- 11/09/22
- Rackspace Technology sees Q4 EP S 4c-6c, consensus 7c
- 11/09/22
- Rackspace Technology reports Q3 EPS 10c, consensus 9c
- 11/09/22
- Notable companies reporting after market close
- 09/26/22
- Rackspace Technology sees Q3 adjusted EPS 8c-10c, consensus 9c
- 10/27/22
- Pinterest sees Q4 revenue up mid single digits, consensus $884.57M
- 10/27/22
- Pinterest reports Q3 adjusted EPS 11c, consensus 6c
- 08/01/22
- Pinterest sees Q3 revenue growth mid-single digits, consensus $713.47M
- 12/05/22
- Nutriband reports Q3 EPS (14c) vs. (23c) last year
- 09/08/22
- Nutriband reports Q2 EPS (12c) vs. (8c) last year
- 09/29/22
- Nike reports Q1 EPS 93c, consensus 92c
- 09/29/22
- Notable companies reporting after market close
- 06/27/22
- Nike sees Q1 revenue growth flat to slightly up sequentially, consensus $12.88B
- 06/27/22
- Nike sees FY23 revenue growth in low double digits, consensus $51.57B
- 10/25/22
- NBT Bancorp reports Q3 EPS 90c, consensus 88c
- 07/25/22
- NBT Bancorp reports Q2 EPS 88c, consensus 84c
- 11/02/22
- MGM Resorts reports Q3 adjusted EPS ($1.39), consensus 23c
- 11/02/22
- Notable companies reporting after market close
- 08/03/22
- MGM Resorts reports Q2 adjusted EPS 3c, consensus 23c
- 08/03/22
- Notable companies reporting after market close
- 10/18/22
- Johnson & Johnson cuts FY22 estimated reported sales view to $93.0B-$93.5B
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted operational EPS view to $10.70-$10.75
- 10/18/22
- Johnson & Johnson narrows FY22 adjusted EPS view to $10.02-$10.07
- 10/18/22
- Johnson & Johnson reports Q3 adjusted EPS $2.55, consensus $2.48
IOVA Iovance Biotherapeutics - 11/03/22
- Iovance Biotherapeutics reports Q3 EPS (63c), consensus (64c)
- 08/04/22
- Iovance Biotherapeutics reports Q2 EPS (63c), consensus (61c)
HZNP Horizon Therapeutics - 11/02/22
- Horizon Therapeutics sees FY22 revenue s $3.59B-$3.61B, consensus $3.56B
- 11/02/22
- Horizon Therapeutics reports Q3 EPS $1.25, consensus $1.01
- 08/03/22
- Horizon Therapeutics cuts FY22 revenue view to $3.53B-$3.6B from $3.9B-$4B
- 08/03/22
- Horizon Therapeutics reports Q2 adjusted EPS $1.07, consensus $1.35
- 11/17/22
- Farfetch reports Q3 adjusted EPS (24c), consensus (28c)
- 08/25/22
- Farfetch reports Q2 EPS (21c), consensus (32c)
ENLV Enlivex Therapeutics - 12/05/22
- Enlivex Therapeutics reports Q3 net loss $5.7M vs $3.4M last year
- 08/22/22
- Enlivex Therapeutics reports Q2 EPS (54c) vs. (17c) last year
- 10/13/22
- Domino's Pizza reports Q3 EPS $2.79, consensus $2.97
- 10/12/22
- Notable companies reporting before tomorrow's open
- 07/21/22
- Domino's Pizza reports Q2 EPS $2.82, consensus $2.90
- 07/20/22
- Notable companies reporting before tomorrow's open
- 11/03/22
- Cushman & Wakefield reports Q3 adjusted EPS 43c, consensus 54c
- 08/04/22
- Cushman & Wakefield reports Q2 adjusted EPS 63c, consensus 54c
- 10/28/22
- Chevron reports Q3 adjusted EPS $5.56, consensus $4.81
- 07/29/22
- Chevron reports Q2 adjusted EPS $5.82, consensus $5.10
- 11/02/22
- CVS Health sees FY23 adjusted EPS $8.70-$8.90, consensus $9.06
- 11/02/22
- CVS Health raises FY22 revenue view to $309B-$314B from $307B-$312B
- 11/02/22
- CVS Health raises FY22 adjusted EPS view to $8.55-$8.65 from $8.40-$8.60
- 11/02/22
- CVS Health reports Q3 adjusted EPS $2.09, consensus $1.99
- 10/27/22
- Credit Suisse reports Q3 net revenue CHF 3.8B vs. CHF 5.43B last year
- 07/27/22
- Credit Suisse reports Q2 net revenue CHF3.6B vs. CHF5.1B last year
- 06/08/22
- Credit Suisse warns loss for Group in Q2 'likely'
- $133.87 /
-10.695 (-7.40%) - 11/30/22
- Salesforce raises FY23 EPS view to $4.92-$4.94, consensus $4.73
- 11/30/22
- Salesforce sees Q4 EPS $1.35-$1.37, consensus $1.34
- 11/30/22
- Salesforce reports Q3 EPS $1.40, consensus $1.21
- 11/30/22
- Notable companies reporting after market close
- $119.37 /
-2.385 (-1.96%) - 11/03/22
- ConocoPhillips reports Q3 EPS $3.60, consensus $3.44
- 11/02/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- ConocoPhillips reports Q2 EPS $3.91, consensus
- 11/01/22
- BP reports Q3 EPS $2.59, consensus $1.94
- 08/02/22
- BP reports Q2 EPS $2.61, consensus $2.13
- 10/27/22
- Apple reports Q4 EPS $1.29, consensus $1.17
- 10/27/22
- Notable companies reporting after market close
- 07/28/22
- Apple reports Q3 EPS $1.20, consensus $1.16
- 07/28/22
- Notable companies reporting after market close
|
